Treatment Information

Back

Colon Cancer treatment details. Biologic therapy.

Institut Gustave Roussy, Villejuif, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Villejuif
Treatments:Biologic therapyHospital:Institut Gustave Roussy
Drugs:Journal:Link
Date:Feb 2014

Description:

Patients:
This study involved 25 EGFR-positive, KRAS-mutant, advanced colorectal cancer patients who had been previously treated. The median patient age was 63 years and 56% were male.

Treatment:
Patients were treated with the biologic therapy agent called imgatuzumab, which is a monoclonal antibody against the EGFR protein that interferes with tumor growth.

Toxicities:
The most severe toxicities were of grade 4 and included grade 3-4 rash, fungal infection, and magnesium deficiency.

Results:
The median overall survival was 9.3 months.

Support:
This study was supported by F. Hoffman La-Roche, Ltd.

Correspondence: Dr. Jean-Charles Soria; email: [email protected]



Back